In Other Journals

A non-invasive, point-of-care proteomic assay may find a role in diagnosing bladder cancer as a useful adjunct to cystoscopy, according to US researchers.1 In a series of 1331 patients at increased risk for bladder cancer, they compared the performance of a nuclear matrix protein (NMP22) urinary assay with that of voided urine cytology, against a reference standard of cystoscopy with biopsy. The NMP22 assay was positive in 44 of 79 patients with cancer, whereas cytology test results were positive in only 12 of 76 patients. Further, the proteomic assay detected four cancers that were not visualised during initial endoscopy.